Intuitive (Nasdaq: ISRG), a global technology leader in minimally
invasive care and the pioneer of robotic-assisted surgery, today
announced executive leadership changes as the company continues
expanding globally and advancing minimally invasive care.
Dave Rosa has been promoted to the role of President, leading
Intuitive’s product, digital, quality, regulatory, supply chain,
manufacturing, and commercial teams. He will oversee the company’s
core business, driving product, digital, and commercial excellence
and delivery of Intuitive’s annual and mid-term strategies and
goals. Rosa is a 27-year company veteran who has held key
leadership positions across the business, including in the
commercial, engineering, clinical development, marketing and
product development organizations. Most recently, Rosa served as
Executive Vice President and Chief Strategy and Growth Officer.
“As Intuitive has grown and demand for robotic-assisted surgery
has increased, we remain focused on our mission to advance
minimally invasive care and our commitment to working with
customers to meaningfully improve patient outcomes,” said Intuitive
Chief Executive Officer Gary Guthart. “Aligning our core business
functions under Dave, a proven and outstanding leader with broad
and deep experience across Intuitive, equips us to meet future
opportunities to collaborate with hospitals and healthcare systems
to address healthcare challenges at significant scale.”
“Our efforts over the past 27 years have created great
opportunities to serve our customers better and in new ways. I look
forward to leading our continued development of innovative,
outcomes-focused products, services, and solutions,” said Rosa.
“Intuitive aims to deliver excellence in customer experience,
industry-leading innovation, and meaningful expansion of minimally
invasive care. My goal is to help the company continue to deliver
on these aims.”
Guthart will continue as Intuitive’s CEO, leading the company
and focusing on Intuitive’s presence in the market, its overall
strategy, governance, and culture, as well as nurturing early-stage
business and product initiatives. Guthart has been with Intuitive
for 27 years, and has served as CEO since 2010.
In addition, Bob DeSantis will assume the newly created role of
Executive Vice President and Chief Strategy and Corporate
Operations Officer, leading strategic planning, operational
structure, and management for the business. Previously, DeSantis
served as Executive Vice President and Chief Product Officer. In
his decade with Intuitive, he has been pivotal in advancing the
development and manufacturing of the company’s industry-leading
robotic platforms.
Rosa and DeSantis will continue to report to Guthart, and all
executive leadership changes are effective immediately.
Intuitive pioneered the field of robotic-assisted minimally
invasive surgery more than two decades ago with the da Vinci
surgical system. Since then, more than 12 million procedures have
been performed using da Vinci systems, with more than
66,000 surgeons worldwide trained on da
Vinci systems.
About IntuitiveIntuitive (Nasdaq: ISRG),
headquartered in Sunnyvale, California, is a global leader in
minimally invasive care and the pioneer of robotic surgery. Our
technologies include the da Vinci surgical system and the Ion
endoluminal system. By uniting advanced systems, progressive
learning, and value-enhancing services, we help physicians and
their teams optimize care delivery to support the best outcomes
possible. At Intuitive, we envision a future of care that is less
invasive and profoundly better, where diseases are identified early
and treated quickly, so patients can get back to what matters
most.
Product and brand names/logos are trademarks or registered
trademarks of Intuitive Surgical or their respective owner.
See www.intuitive.com/trademarks.
For more information, please visit the Company’s
website at www.intuitive.com.
Forward-Looking StatementsThis press release
contains forward-looking statements, including statements regarding
executive leadership changes, the Company’s ability to address
healthcare challenges at significant scale, the Company’s continued
development of innovative, outcomes-focused products, services and
solutions and the Company’s aim to deliver excellence in customer
experience, industry-leading innovation and meaningful expansion of
minimally invasive care across product and digital solutions,
clinical applications and geographies. These statements reflect the
judgment of the Company's management and involve a number of risks
and uncertainties that could cause actual results to differ
materially from those suggested by the forward-looking statements.
These forward-looking statements should be considered in light of
various important factors, including, but not limited to, the
following: the overall macroeconomic environment, which impacts
customer spending and the Company’s costs, including increased
inflation and interest rates, the conflict in Ukraine, disruption
to the Company’s supply chain; curtailed or delayed capital
spending by hospitals; delays in surgeon training; delays in
gathering clinical evidence; delays in obtaining new product
approvals, clearances, or certifications from regulatory
authorities, or notified bodies; the impact of global and regional
economic and credit market conditions on healthcare spending; the
risk of the Company’s inability to comply with complex regulations;
regulatory approvals, clearances, certifications, and restrictions
or any dispute that may occur with any regulatory body; guidelines
and recommendations in the healthcare and patient communities;
healthcare reform legislation in the U.S. and its impact on
hospital spending, reimbursement, and fees levied on certain
medical device revenues; changes in hospital admissions and actions
by payers to limit or manage surgical procedures; the timing and
success of product development and market acceptance of developed
products; the results of any collaborations, in-licensing
arrangements, joint ventures, strategic alliances, or partnerships,
including the joint venture with Shanghai Fosun Pharmaceutical
(Group) Co., Ltd.; the Company’s completion of and ability to
successfully integrate acquisitions; intellectual property
positions and litigation; competition in the medical device
industry and in the specific markets of surgery in which the
Company operates; risks associated with the Company’s operations
and any expansion outside of the United States; unanticipated
manufacturing disruptions or the inability to meet demand for
products; the Company’s reliance on sole-sourced and single-sourced
suppliers; the results of legal proceedings to which we are or may
become a party; adverse publicity regarding the Company and the
safety of the Company’s products and adequacy of training; the
impact of changes to tax legislation, guidance, and
interpretations; changes in tariffs, trade barriers, and regulatory
requirements; and other risks and uncertainties. Readers are
cautioned not to place undue reliance on these forward-looking
statements, which speak only as of the date of this press release
and which are based on current expectations and are subject to
risks, uncertainties, and assumptions that are difficult to
predict, including those risk factors identified under the heading
“Risk Factors” in the Company’s Annual Report on Form 10-K for the
year ended December 31, 2022, and the Company’s Quarterly report on
Form 10-Q for the quarter ended March 31, 2023 as updated by the
Company’s other filings with the Securities and Exchange
Commission. The Company’s actual results may differ materially and
adversely from those expressed in any forward-looking statement,
and the Company undertakes no obligation to publicly update or
release any revisions to these forward-looking statements, except
as required by law. Statements using words such as “estimates,”
“projects,” “believes,” “anticipates,” “plans,” “expects,”
“intends,” “may,” “will,” “could,” “should,” “would,” “targeted,”
and similar words and expressions are intended to identify
forward-looking statements.
ContactUS/GLOBAL: Global Public
AffairsIntuitive Surgicalcorp.comm@intusurg.com+1-202-997-7373
Source: Intuitive Surgical, Inc.
Intuitive Surgical (NASDAQ:ISRG)
Gráfico Histórico do Ativo
De Mar 2024 até Abr 2024
Intuitive Surgical (NASDAQ:ISRG)
Gráfico Histórico do Ativo
De Abr 2023 até Abr 2024